

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
VEGF receptor 1 (FLT1) expression as a marker for predicting response to anti-placental growth factor (PGF; PlGF) therapies	<p>FLT1 expression could help predict whether cancer patients will respond to anti-PlGF therapies. In xenograft mice implanted with 12 different human tumor cell lines, 3 cell lines sensitive to anti-PlGF antibodies expressed FLT1, whereas the 9 cell lines resistant to anti-PlGF antibodies did not. Next steps could include validating the results in clinical trials.</p> <p>ThromboGenics N.V., Roche and BioInvent International AB are developing TB-403, an anti-PlGF antibody that is in Phase I testing to treat various cancers.</p> <p>SciBX 4(28); doi:10.1038/scibx.2011.811 Published online July 21, 2011</p>	Patent and licensing status undisclosed	<p>Yao, J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 27, 2011; doi:10.1073/pnas.1109029108</p> <p>Contact: Napoleone Ferrara, Genentech Inc., South San Francisco, Calif. e-mail: nf@gene.com</p>